tiprankstipranks

Lexaria’s Oral Liraglutide Shows Promise in Reducing Adverse Events

Story Highlights
Lexaria’s Oral Liraglutide Shows Promise in Reducing Adverse Events

Don’t Miss TipRanks’ Half-Year Sale

Lexaria Bioscience ( (LEXX) ) just unveiled an announcement.

Lexaria Bioscience has announced promising results from its human clinical study comparing oral DehydraTECH-liraglutide capsules to the injected form of liraglutide, Saxenda®. The study showed a significant reduction in adverse events with the oral formulation, particularly in nausea and gastrointestinal issues, and met its primary endpoint of demonstrating safety and tolerability. These findings suggest a potential pathway for FDA registration of an oral version of liraglutide, addressing an unmet market need and offering a competitive alternative to existing injectable forms.

The most recent analyst rating on (LEXX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.

More about Lexaria Bioscience

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on enhancing the delivery and effectiveness of drugs using its patented DehydraTECH technology. The company is involved in the pharmaceutical industry, specifically targeting the delivery of GLP-1 drugs, which are used for treating conditions like diabetes and obesity.

Average Trading Volume: 94,078

Technical Sentiment Signal: Sell

Current Market Cap: $20.46M

For detailed information about LEXX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1